These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10232704)

  • 1. Aldose reductase and the development of renal disease in diabetic dogs.
    Kern TS; Engerman RL
    J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
    Chang WP; Dimitriadis E; Allen T; Dunlop ME; Cooper M; Larkins RG
    Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats.
    Mauer SM; Steffes MW; Azar S; Brown DM
    Diabetes; 1989 Jul; 38(7):839-46. PubMed ID: 2525493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies.
    Kassab JP; Guillot R; Andre J; Claperon N; Bellon G; Feldmann G; Peyroux J; Sternberg M
    Biochem Pharmacol; 1994 Aug; 48(5):1003-8. PubMed ID: 8093087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorbinil does not prevent hyperfiltration, elevated ultrafiltration pressure and albuminuria in streptozotocin-diabetic rats.
    Körner A; Celsi G; Eklöf AC; Linné T; Persson B; Aperia A
    Diabetologia; 1992 May; 35(5):414-8. PubMed ID: 1521721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL; Kern TS; Garment MB
    J Diabetes Complications; 1993; 7(4):241-5. PubMed ID: 8219367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
    Bank N; Coco M; Aynedjian HS
    Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorbinil does not prevent galactose-induced glomerular capillary basement membrane thickening in the rat.
    Das A; Frank RN; Zhang NL
    Diabetologia; 1990 Sep; 33(9):515-21. PubMed ID: 2123806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal hemodynamics in experimentally galactosemic dogs and diabetic dogs.
    Kern TS; Engerman RL
    Metabolism; 1991 May; 40(5):450-4. PubMed ID: 1902544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
    McCaleb ML; McKean ML; Hohman TC; Laver N; Robison WG
    Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E; Edelist T; Varagiannis E
    Pharmacology; 1986; 32(1):52-60. PubMed ID: 3080763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glomerular basement membrane thickening in streptozotocin diabetic rats despite treatment with an aldose reductase inhibitor.
    Osterby R; Gundersen HJ
    J Diabet Complications; 1989; 3(3):149-53. PubMed ID: 2528558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase activity and basement membrane thickening.
    Frank RN
    Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
    Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
    Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.